| 产品详情 |
| Edit |   |
|---|
| Product Name | BMP Inhibitor III, LDN-212854 |
|---|
| Description | Purity ~98% (HPLC). A cell-permeable pyrazolopyrimidinylquinoline that is superior to Dorsomorphin and DMH1 as an ATP-site-targeting, ALK1/2 inhibitor (IC50 = 2.40 and 1.30nM, respectively; [ATP] = 6uM) with respect to both potency and selectivity over ALK3/4/5 (IC50 = 0.858, 2.133, and 9.276uM, respectively). Also a potent RIPK2 inhibitor (IC50 = 6nM) with reduced potency against ABL1/c-abl, PDGFR-beta, ALK3, and PDGFR-alpha (IC50 = 40, 68, 85.8, and 650nM, respectively) and little inhibitory activity toward a panel of more than 190 kinases. Effectively inhibits ALK2- and ALK3-mediated C2C12 osteogenic differentiation (IC50 = 10 and 40.5nM, respectively) in vitro and prevents constitutively active ALK2 Q207D mutant-induced heterotopic ossification in mice (6mg/kg/12h via i.p.) in vivo. Primary Target: ALK1/2/3 Secondary Target: RIP, Abl & PDGFR Solubility: DMSO |
|---|
| Size | 5mg |
|---|
| Concentration | n/a |
|---|
| Applications | n/a |
|---|
| Other Names | BMP Inhibitor III, LDN-212854 (Abl Inhibitor V, LDN212854, Bone Morphogenetic Protein Inhibitor III, PDGFR Tyrosine Kinase Inhibitor XXIV, RIP2 Inhibitor I, RIPK2 Inhibitor I, 5-(6-(4-(Piperazin-1-yl)phenyl)pyrazolo[1,5-a]pyrimidin-3-yl)quinoline) |
|---|
| Gene, Accession, CAS # | n/a |
|---|
| Catalog # | 217225 |
|---|
| Price | |
|---|
| Order / More Info | BMP Inhibitor III, LDN-212854 from UNITED STATES BIOLOGICAL |
|---|
| Product Specific References | n/a |
|---|
| 产品资料 |
|
|